Resveratrol solid lipid nanoparticles to trigger credible inhibition of doxorubicin cardiotoxicity

References

• Barry E, Alvarez JA, Scully RE, et al. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother. 2007;8:1039–1058. doi:10.1517/14656566.8.8.103917516870
   PubMed Web of Science ®Google Scholar
• Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis. 2007;49:330–352. doi:10.1016/j.pcad.2006.10.00217329180
   PubMed Web of Science ®Google Scholar
• Lin ST, Chou HC, Chen YW, Chan HL. Redox-proteomic analysis of doxorubicin-induced altered thiol activity in cardiomyocytes. Mol Biosyst. 2013;9:447–456. doi:10.1039/c2mb25367d23340498
   PubMedGoogle Scholar
• Tallaj JA, Franco V, Rayburn BK, et al. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant. 2005;24:2196–2201. doi:10.1016/j.healun.2004.12.10816364871
   PubMed Web of Science ®Google Scholar
• Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639–1642. doi:10.1038/nm.291923104132
   PubMed Web of Science ®Google Scholar
• Oktem G, Uysal A, Oral O, et al. Resveratrol attenuates doxorubicin-induced cellular damage by modulating nitric oxide and apoptosis. Exp Toxicol Pathol. 2012;64:471–479. doi:10.1016/j.etp.2010.11.00121144718
   PubMedGoogle Scholar
• Salehi B, Mishra AP, Nigam M, et al. Resveratrol: a double-edged sword in health benefits. Biomedicines. 2018;6:E91. doi:10.3390/biomedicines603009130205595
   PubMed Web of Science ®Google Scholar
• Zhang C, Feng Y, Qu S, et al. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc Res. 2011;80:538–545. doi:10.1093/cvr/cvr022
   Google Scholar
• Gu J, Hu W, Song ZP, et al. Resveratrol-induced autophagy promotes survival and attenuates doxorubicin-induced cardiotoxicity. IntImmunopharmacol. 2016;32:1–7. doi:10.1016/j.intimp.2016.01.002
   PubMed Web of Science ®Google Scholar
• Khan AR, Yang X, Fu M, Zhai G. Recent progress of drug nanoformulations targeting to brain. J Control Release. 2018;291:37–64. doi:10.1016/j.jconrel.2018.10.00430308256
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165–196.11311991
   PubMed Web of Science ®Google Scholar
• Shrotriya SN, Ranpise NS, Vidhate BV. Skin targeting of resveratrol utilizing solid lipid nanoparticle-engrossed gel for chemically induced irritant contace dermatitis. Drug Deliv Transl Res. 2017;7:37–52. doi:10.1007/s13346-016-0350-727981502
   PubMed Web of Science ®Google Scholar
• Wang W, Zhang L, Chen T, et al. Anticancer effects of resveratrol-loaded solid lipid nanoparticles on human breast cancer cells. Molecules. 2017;22:E1814. doi:10.3390/molecules2211181429068422
   PubMed Web of Science ®Google Scholar
• Barbosa JP, Neves AR, Silva AM, et al. Nanostructured lipid carriers loaded with resveratrol modulate human dendritic cells. Int J Nanomed. 2016;11:3501–3516. doi:10.2147/IJN.S108694
   PubMed Web of Science ®Google Scholar
• Singh A, Ahmad I, Ahmad S, et al. A novel monolithic controlled delivery system of resveratrol for enhanced hepatoprotection: nanoformulation development, pharmacokinetics and pharmacodynamics. Drug Dev Ind Pharm. 2016;42:1524–1536. doi:10.3109/03639045.2016.115103226902951
   PubMed Web of Science ®Google Scholar
• Jose S, Anju SS, Cinu TA, et al. In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery. Int J Pharm. 2014;474:6–13. doi:10.1016/j.ijpharm.2014.08.00325102112
   PubMed Web of Science ®Google Scholar
• Oliveira RR, Carriao MS, Pacheco MT, et al. Triggered release of paclitaxel from magnetic solid lipid nanoparticles by magnetic hyperthermia. Mater Sci Eng C Mater Biol Appl. 2018;92:547–553. doi:10.1016/j.msec.2018.07.01130184781
   PubMed Web of Science ®Google Scholar
• Wu X, Hu Z, Nizzero S, et al. Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity. J Control Release 2017;268:92–101. doi:10.1016/j.jconrel.2017.10.012
   Google Scholar
• Gu J, Fan YQ, Zhang HL, et al. Resveratrol suppresses doxorubicin-induced cardiotoxicity by disrupting E2F1 mediated autophagy inhibition and apoptosis promotion. Biochem Pharmacol. 2018;150:202–213. doi:10.1016/j.bcp.2018.02.02529475062
   PubMed Web of Science ®Google Scholar
• Wu Z, Chen Q, Ke D, et al. Emodin protects against diabetic cardiomyopathy by regulating the AKT/GSK-3beta signaling pathway in the rat model. Molecules. 2014;19:14782–14793. doi:10.3390/molecules19091478225232702
   PubMed Web of Science ®Google Scholar
• Shabalala S, Muller CJF, Louw J, Johnson R. Polyphenols, autophagy and doxorubicin-induced cardiotoxicity. Life Sci. 2017;180:160–170. doi:10.1016/j.lfs.2017.05.00328478263
   PubMed Web of Science ®Google Scholar
• Cao Y, Shen T, Huang X, et al. Astragalus polysaccharide restores autophagic flux and improves cardiomyocyte function in doxorubicin-induced cardiotoxicity. Oncotarget. 2017;8:4837–4848. doi:10.18632/oncotarget.1359627902477
   PubMedGoogle Scholar
• Zhang YY, Yi M, Huang YP. Oxymatrine ameliorates doxorubicin-induced cardiotoxicity in rats. Cell Physiol Biochem. 2017;43:626–635. doi:10.1159/00048047128946137
   PubMedGoogle Scholar
• Sahu BD, Kumar JM, Kuncha M, et al. Baicalein alleviates doxorubicin-induced cardiotoxicity via suppression of myocardial oxidative stress and apoptosis in mice. Life Sci. 2016;144:8–18. doi:10.1016/j.lfs.2015.11.01826606860
   PubMed Web of Science ®Google Scholar
• Sun J, Sun G, Meng X, et al. Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro. PLoS One. 2013;8:e64526. doi:10.1371/journal.pone.006452623724057
   PubMed Web of Science ®Google Scholar
• Shoukry HS, Ammar HI, Rashed LA, et al. Prophylactic supplementation of resveratrol is more effective than its therapeutic use against doxorubicin induced cardiotoxicity. PLoS One. 2017;12:e0181535. doi:10.1371/journal.pone.018153528727797
   PubMedGoogle Scholar
• Caddeo C, Teskac K, Sinico C, Kristl J. Effect of resveratrol incorporated in liposomes on proliferation and UV-B protection of cells. Int J Pharm. 2008;363:183–191. doi:10.1016/j.ijpharm.2008.07.02418718515
   PubMed Web of Science ®Google Scholar
• Al-Harthi SE, Alarabi OM, Ramadan WS, et al. Amelioration of doxorubicin-induced cardiotoxicity by resveratrol. Mol Med Rep. 2014;10:1455–1460. doi:10.3892/mmr.2014.238425059399
   PubMed Web of Science ®Google Scholar